Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026)
Kamada (KMDA) reported Total Non-Current Liabilities of $63.9 million for Q1 2026, down 3.39% on a YoY basis from $66.1 million in Q1 2025, and up 2.59% quarter-over-quarter from $62.2 million in Q4 2025.
Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Kamada has reported Total Non-Current Liabilities for 13 years, with the latest figure at $63.9 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 3.39% year-over-year to $63.9 million; the trailing twelve-month figure through Mar 2026 stood at $63.9 million (down 3.39% YoY), and the FY2025 full-year result was $62.2 million, down 1.82% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $63.9 million, up from $62.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $85.7 million in Q1 2022, with the low at $72712.0 in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $58.6 million across 5 years, with a median of $62.4 million in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 99.92% — and 2024, when it jumped 81714.56%.
- Kamada's Total Non-Current Liabilities stood at $70.7 million in 2022, then decreased by 13.25% to $61.3 million in 2023, then gained by 3.44% to $63.4 million in 2024, then declined by 1.82% to $62.2 million in 2025, then gained by 2.59% to $63.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $63.9 million (Q1 2026), $62.2 million (Q4 2025), and $64.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Kamada | 504.70 | -73.15 Mn | 19.12 Mn | 63.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.86 Mn |
| Dec 31, 2025 | 62.25 Mn |
| Sep 30, 2025 | 64.14 Mn |
| Jun 30, 2025 | 62.45 Mn |
| Mar 31, 2025 | 66.10 Mn |
| Dec 31, 2024 | 63.40 Mn |
| Sep 30, 2024 | 61.94 Mn |
| Jun 30, 2024 | 58.99 Mn |
| Mar 31, 2024 | 59.49 Mn |
| Dec 31, 2023 | 61.29 Mn |
| Sep 30, 2023 | 61.39 Mn |
| Jun 30, 2023 | 71.81 Mn |
| Mar 31, 2023 | 72,712.00 |
| Dec 31, 2022 | 70.65 Mn |
| Sep 30, 2022 | 77,936.00 |
| Jun 30, 2022 | 82.88 Mn |
| Mar 31, 2022 | 85.72 Mn |
| Dec 31, 2021 | 87.79 Mn |
| Sep 30, 2021 | 8.33 Mn |
| Jun 30, 2021 | 7.86 Mn |